The Annals
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 3, pp. 454. DOI 10.1345/aph.1C025b
© 2003 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in The Annals
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Absher, R. K
Right arrow Articles by Parker, M. H
Right arrow Search for Related Content
PubMed
Right arrow Articles by Absher, R. K
Right arrow Articles by Parker, M. H

Authors' Reply

Randall K Absher, PharmD BCPS

Pharmacy Clinical Coordinator Pharmacy Department Wesley Long Community Hospital 501 North Elam Avenue Greensboro, North Carolina 27403-1199 FAX 336/832-1960 E-mail randy.absher{at}mosescone.com

M Elisabeth Moore, MEd RD CNSD LDN

Nutrition Support Dietitian Wesley Long Community Hospital

Mary H Parker, PharmD BCPS

Director, Cardiovascular Risk Reduction Clinics LeBauer Healthcare Greensboro, North Carolina

Published Online, February 3, 2003. www.theannals.com, DOI 10.1345/aph.1C025b

We thank Lindh for his interest in our work and for his insights regarding potential mechanisms for the association between African American ethnicity and large warfarin dosage requirements.

We concur that differences in CYP2C9 polymorphism prevalence as described by Lindh could explain larger mean warfarin dosage requirements in African Americans when compared with white patients. The CYP2C9 polymorphisms described to date, however, are less likely to explain the specific frequency distributions we observed. In a further analysis of our data, we omitted the lowest warfarin-dosage quartile to ostensibly exclude the majority of subjects of all ethnicities with slow-metabolizer CYP2C9 polymorphisms. This transformation still yielded disparate frequency distributions for warfarin dosages among subjects of different ethnicities, with disproportionate numbers of African Americans requiring larger warfarin dosages. The relatively small sample size of our study cohort precludes definitive inferential analysis under this approach. We believe further exploration in larger groups of patients is appropriate.


Related articles in The Annals:

Comment: patient-specific factors predictive of warfarin dosage requirements
Jonatan D Lindh
The Annals 2003 37: 454. [Full Text]  




This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in The Annals
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Absher, R. K
Right arrow Articles by Parker, M. H
Right arrow Search for Related Content
PubMed
Right arrow Articles by Absher, R. K
Right arrow Articles by Parker, M. H

homecopy help contact us subscription past issues search current issue